Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes by Bolli, G B et al.
o
r
i
g
i
n
a
l
a
r
t
i
c
l
e
Diabetes, Obesity and Metabolism 13: 251–257, 2011.
© 2011 Blackwell Publishing Ltd original article
Comparative pharmacodynamic and pharmacokinetic
characteristics of subcutaneous insulin glulisine and insulin
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Aims: A multinational, randomized, double-blind, two-way crossover trial to compare the pharmacokinetic and pharmacodynamic properties of
bolus, subcutaneously administered insulin glulisine (glulisine) and insulin aspart (aspart) in insulin-na¨ıve, obese subjects with type 2 diabetes.
Methods: Thirty subjects [9/21 females/males; mean ± SD age: 60.7 ± 7.7 years; body mass index (BMI): 33.5 ± 3.3k g / m 2;d u r a t i o no f
diabetes: 6.8 ± 4.6y e a r s ;H b A 1 c :7 .1 ± 0.8%] were included in the analysis. They fasted overnight and then received a 0.2 U/kg subcutaneous
dose of glulisine or aspart 2 min before starting a standardized test meal, 7 days apart, according to a randomization schedule. Blood samples
were taken every 15 min, starting 20 min before the meal and ending 6 h postprandially.
Results: The area under the absolute glucose concentration–time curve between 0 and 1 h after insulin injection and maximal glucose
concentration was signiﬁcantly lower with glulisine than with aspart (p = 0.0455 and 0.0337, respectively). However, for the total study period,
plasma glucose concentration was similar for glulisine and aspart. Peak insulin concentration was signiﬁcantly higher for glulisine than for insulin
aspart (p < 0.0001). Hypoglycaemic events (≤70 mg/dl with or without symptoms) occurred in 13 and 16 subjects treated with glulisine and
aspart, respectively, but there were no cases of severe hypoglycaemia requiring intervention.
Conclusions: Glulisine was associated with lower glucose levels during the ﬁrst hour after a standard meal; the remaining glucose proﬁles
were otherwise equivalent, with higher insulin levels observed throughout the study period.
Keywords: insulin analogues, insulin aspart, insulin glulisine, insulin therapy, obesity, obesity therapy, pharmacodynamics, pharmacokinetics,
type 2 diabetes
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Introduction
The ultimate goal of therapy in type 2 diabetes (T2DM) is to
achieve near-normoglycaemia [1]. The Global Task Force on
Glycaemic Control recommended HbA1c levels of less than
6.5% as a good target for certain people with T2DM [2],
although it also stated that HbA1c and blood glucose targets
should be individualized, taking into account factors such
as age, existing complications, risk of future complications,
diabetes duration and risk of hypoglycaemia. Type 2 diabetes
is generally characterized by the presence of relative insulin
deﬁciency, including postprandial insulin deﬁciency [3], in the
presence of insulin resistance. Therefore, an important facet of
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T2DM treatment is to support and/or supplement the insulin
deﬁcit to replicate as closely as possible the normal insulin
secretory pattern, including an early response to a nutrient
challenge. The time–action proﬁle of subcutaneously injected
regular human insulin (RHI) provides a slow onset of action,
with a peak effect at 3 h after dosing and a relatively prolonged
durationofactionbeyond8 h [4].Thisrequirestheinsulintobe
administered up to 1 h premeal in an attempt to accommodate
these deﬁciencies.
In response to these limitations of RHI, three rapid-acting
insulinanalogueshavebeenintroduced:insulinaspart(aspart),
insulin glulisine (glulisine) and insulin lispro (lispro). These
analogues all have a rapid onset of action (within 30–60 min)
and a peak action within 2 h to allow for appropriate control
of postprandial glucose (PPG) ﬂuctuations when given within
5 min preprandially [5]. Glulisine differs from RHI by the
replacementofasparaginebylysineatpositionB3andlysineby
glutamicacidat B29 [6]. Themodiﬁcationsin glulisineallowit
toexistasmorestabledimersandmonomersatpharmaceuticaloriginal article DIABETES, OBESITY AND METABOLISM
concentrations,allowingglulisinetobesuspendedinazinc-free
buffer,unlikeRHIandotherrapid-actinginsulinanalogues [6].
Lispro differs in that the lysine and proline residues at the
C-terminal end of the B chain are reversed, which prevents the
formation of insulin dimers and hexamers. Aspart differs in
that the amino acid residue at position B28 is substituted with
aspartic acid, which increases charge repulsion to inhibit the
formation of hexamers [6].
Glulisine has been shown to have a more rapid onset
of action and a shorter duration of action compared with
RHI in obese subjects without diabetes [7]. In addition,
glulisine was shown to have a faster onset of action in obese
subjects without diabetes [8] and faster absorption with higher
postprandial insulin levels in people with T2DM compared
with lispro [9]. Similar ﬁndings have also been reported in
healthy individuals [10] and individuals with type 1 diabetes
(T1DM) [11,12]. A recent study in healthy individuals has also
shownamorerapidonsetofactionforglulisinecomparedwith
aspart [13].
To date, however, no study has directly compared the
pharmacokinetic (PK) and pharmacodynamic (PD) properties
of glulisine with those of aspart in people with T2DM.
Therefore, the aim of this study was to conduct such a study in
obese subjects with T2DM with the comparative insulins given
immediately before a standardized test meal.
Materials and Methods
This was a multinational, randomized, double-blind, two-way
crossover trial comparing the PK and PD characteristics of
glulisine with those of aspart.
Study Population
Obese[bodymassindex(BMI)30–40 kg/m2]malesorfemales
aged 18–70 years with T2DM for at least 1 year, treated with
oral hypoglycaemic agents (OHAs) for at least 6 months and
with HbA1c levels of less than 8.5% were eligible for this study.
Subjects were excluded if they had T1DM or were currently
using insulin. Further exclusion criteria were pregnancy
or breastfeeding, taking medications known to inﬂuence
insulin sensitivity (e.g. corticosteroids), a history of acute
metaboliccomplicationsinthepast3 months,recurrentsevere
hypoglycaemiaor hypoglycaemia unawareness, impaired renal
or hepatic function and any history of drug or alcohol abuse.
All subjects provided written informed consent and the
study was approved by an independent ethics committee at
each of the three study sites (Perugia, Italy; Nantes, France and
Cardiff, UK).
Study Design and Treatment
Subjects attended a screening visit, performed 1–2 weeks
before the ﬁrst study day, to conﬁrm eligibility. At this
visit, baseline characteristics, vital signs and laboratory tests
(haematology, clinical chemistry, C-peptide level, HbA1c level
and urinalysis) were evaluated after a 12-h fast. On the ﬁrst
study day, the subjects arrived at the respective research
centres at approximately 8 a.m., after fasting and omitting
their OHAs for 12 h before the visit. In accordance with the
randomization scheme, subjects received a 0.2 U/kg dose of
either glulisine or aspart subcutaneously within 2 min before
startingastandardizedmeal(692 kcal:54%carbohydrate,17%
proteinand28%lipid),whichtheyhadtoﬁnishwithin30 min.
Aftera7-daywashoutperiod,thesameprocedurewasrepeated
using the alternative insulin preparation.
Blood samples were collected at −20 and −10 min and
immediately before the meal (0 min), every 10 min for the
ﬁrst 2 h after the meal and then every 15 min for the
remaining 4-h period of the study. Plasma glucose, insulin,
C-peptide (Invitron, Monmouth, UK) and non-esteriﬁed fatty
acid (NEFA; Wako NEFA-C kit, Wako Chemicals, Neuss,
Germany) levels were determined using validated techniques.
Aspart (Capio Diagnostics AS, Copenhagen, Denmark) and
glulisine (Linco Research, Missouri,USA) concentrationswere
determined using analogue-speciﬁc assay kits at a central
laboratory. All adverse events and episodes of hypoglycaemia
were recorded.
Outcome Measures
TheprimaryobjectiveofthisstudywastoassessthePDeffectof
glulisine compared with aspart on PPG excursions during the
ﬁrst hour after a standard meal, as measured by the area under
the glucose concentration–time curve (AUC) between 0 and
1 h after insulin injection (AUC0–1 h). Secondary objectives
included assessment of the PD effects of these insulins on
PPG excursions up to 6 h after a standard meal (AUC0–6 h)
and assessment of the postprandial insulin excursion after
a standard meal in each treatment group. Other objectives
were to evaluate C-peptide and NEFA levels in each treatment
group.
Statistical Analysis
Pharmacodynamic parameters were derived from the individ-
ual glucose concentration proﬁles and PK parameters from
the serum aspart and glulisine concentrations. The AUCs were
calculatedaccordingtothelineartrapezoidalrule[14].PKanal-
yses were carried out using a non-compartmental approach in
order to determine maximum insulin concentration (Cmax)
and time to maximum insulin concentration (Tmax) parame-
ters from serum insulin concentrations. Also, the incremental
AUCs(0–1,0–2,0–4and0–6hforPDandPK),maximum
glucose concentration (GLUmax), maximum incremental glu-
cose excursion ( GLUmax)a n dCmax were analysedby analysis
ofvariancewithsubject,treatment,sequencegroupandperiod
effects. Two-sided 90% conﬁdence intervals (CIs) were calcu-
latedforthemeandifferencesormeanratios.Timeto GLUmax
andtimetofractionoftotalglucoseAUC(10and20%)andcor-
responding PK parameters [Tmax and time to fraction of total
insulin AUC (10 and 20%)] were analysed using Wilcoxon’s
signed rank test and Hodges–Lehmann 90% CIs were calcu-
lated for the median difference, as previously described [15].
Superiority testing was carried out at the 5% signiﬁcance level.
For any given variable (except time measurements), glulisine
and aspart were considered to be clinically similar if the dif-
ference between them was non-signiﬁcant and if the two-sided
90% CIs for the ratios of the means were within 80–125%.
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PK and PD analyses were performed in all subjects who
completed the study with no major protocol deviations and
who had data considered as evaluable. Safety (hypoglycaemia
and adverse events) was assessed for all subjects who were
exposed to study treatment.
Results
Subject Disposition
A total of 43 subjects were screened, of whom six were
excluded because of having a BMI outside the predeﬁned
range (n = 2), an HbA1c level of more than 8.5% (n = 2),
age over 70 years (n = 1) or taking prohibited medication
(n = 1). Therefore, 37 subjects [mean (± standard deviation)
age 60.3 ± 8.3y e a r s ,B M I3 3 .7 ± 3.3k g / m 2, diabetes duration
7.3 ± 4.9y e a r s ,H b A 1 c7 .1 ± 0.8%] were randomized. Of the
37 subjects randomized, seven were subsequently excluded
from the PK and PD analyses: one for premature withdrawal
after the ﬁrst study day (having received aspart) and six
for major protocol deviations [two subjects with medical
conditions at inclusion who were erroneously included; one
eachforuseofcorticosteroidsduringthestudy,missingPK/PD
values in the ﬁrst hour after drug administration, unusable PK
assessments (very low aspart plasma levels, incompatible with
aspart administration) and duration of meal intake longer
than 30 min (85 min)]. The latter two subjects were excluded
after the database lock, following a recommendation by the
Steering Committee. Therefore, 30 subjects were included in
theﬁnalanalysisandthebaselinecharacteristicsarerepresented
in Table 1. There were no differences between the subjects
included in the ﬁnal analysis and all randomized subjects (data
not shown). The mean doses of glulisine and aspart were
19.5 ± 2.7a n d1 9 .4 ± 2.7 U, respectively.
Pharmacodynamics
Mean blood glucose levels at baseline were 137.4 ± 33.2
and 140.5 ± 32.5 mg/dl for the glulisine and aspart groups,
respectively. The plasma glucose concentrations over time are
s h o w ni nﬁ g u r e1 .B o t hm e a nA U C 0–1 h (149 vs. 158 mg·h/dl;
p = 0.0455) and mean GLUmax (170 vs. 181 mg/dl; p =
0.0337)weresigniﬁcantlylowerwithglulisinethanwithaspart.
Point estimates (glulisine/aspart) for AUC0–1 h and GLUmax
were 94% (90% CI: 90–99) and 94% (90% CI: 90–99),
respectively (Table 2). No statistically signiﬁcant differences
were observed with baseline-subtracted data in any of the
periods analysed (data not shown).
The AUC ratios for AUC0–1h/AUC0–6 h (p = 0.0334) and
AUC0–2 h/AUC0–6 h (p = 0.0341) were signiﬁcantly lower for
glulisine than aspart, with point estimates of 95% (90% CI:
92–99) and 96% (90% CI: 94–99), respectively (Table 2).
Moreover, taking into account the total study duration (6 h),
the overall plasma glucose concentration was similar between
groups treated with glulisine and aspart.
Mean C-peptide plasma concentration proﬁles were similar
after glulisine and aspart injections (data not shown),
with maximum concentrations of 2.08 and 2.07 pmol/ml,
respectively, occurring at 90 min for both insulin analogues.
Mean NEFA concentrations decreased from 0.50 to
0.11 mmol/l at 180 min with glulisine and from 0.51 to
0.11 mmol/l at 120 min with aspart; the NEFA concentrations
then increased to 0.32 and 0.31 mmol/l with glulisine and
aspart, respectively.
Pharmacokinetics
Table 2 also represents the PK results derived from the
insulin concentration proﬁles illustrated in ﬁgure 2a. Peak
insulin concentration was signiﬁcantly higher for glulisine
than for aspart (geometric mean of 534 vs. 363 pmol/l;
p < 0.0001; ﬁgure 2b). Although Tmax tended to be longer
with glulisine (median of 120.0 vs. 93.0 min), this difference
was not signiﬁcant (p = 0.5133). Glulisine was associated with
signiﬁcantly higher AUCs for all four measurement durations
(0–1, 0–2, 0–4 and 0–6h; all: p< 0.0001), with point
estimatesformeanratios(glulisine/aspart)rangingfrom155%
(90% CI: 141–171) for AUC0–6 hto 197% (90% CI: 157–248)
forAUC0–1h.IntermsofAUCratios,onlyAUC0–1h/AUC0–6h
was signiﬁcantly different between the groups, with the value
Table 1. Baseline characteristics of the study subjects.
Sequence glulisine/aspart
(n = 16)
Sequence aspart/glulisine
(n = 14)
All
(n = 30)
Females/males, n 3/13 6/8 9/21
Age, years∗ 61.2 ± 7.75 9 .7 ± 8.36 0 .7 ± 7.7
Weight, kg∗ 100.4 ± 16.19 4 .1 ± 10.79 6 .3 ± 14.3
Height, cm∗ 173.1 ± 8.6 166.3 ± 7.2 169.4 ± 8.7
BMI, kg/m2∗ 33.3 ± 3.43 4 .0 ± 3.33 3 .5 ± 3.3
Diabetes duration, years∗ 6.3 ± 4.07 .5 ± 5.36 .8 ± 4.6
HbA1c, %∗ 7.0 ± 0.87 .2 ± 0.87 .1 ± 0.8
Oral hypoglycaemic agents, n (%) 16 (100) 14 (100) 30 (100)
Biguanides 15 (3.8) 14 (100) 29 (96.7)
Sulphonylureas 5 (31.3) 9 (64.3) 14 (46.7)
Thiazolidinediones 3 (18.8) 3 (21.4) 6 (20.0)
Glinides 1 (6.3) 1 (7.1) 2 (6.7)
BMI, body mass index.
∗Data are mean ± standard deviation.
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Figure 1. Mean plasma glucose concentrations over time. SEM, standard error of the mean.
of this ratio for glulisine being 127% of the equivalent ratio for
aspart (90% CI: 106–152; p = 0.0340; Table 2).
Hypoglycaemia and Safety Parameters
A total of 13 (36.1%) subjects given glulisine and 16
(43.2%) subjects receiving aspart experienced an episode of
hypoglycaemia (blood glucose <70 mg/dl with or without
symptoms). Among these, 10 and 15 subjects, respectively,
experienced an episode of hypoglycaemia 3–6 h after the
insulin administration. The remaining episodes occurred 30,
110and135 minafterglulisineadministrationand60 minafter
aspart administration. Five and eight subjects, respectively,
experienced an episode of hypoglycaemia with blood glucose
levels below 56 mg/dl. None of the episodes was considered to
be severe nor required intervention.
Five treatment-emergent adverse events were reported in
four subjects, including injection-site pain (glulisine, one;
aspart, one), headache (glulisine, one; aspart, one) and nausea
(aspart, one). None of the adverse events was reported as
serious.
Discussion
This two-way crossover study is the ﬁrst to compare the
PK/PD proﬁles of glulisine and aspart in people with T2DM,
given a standard meal under identical baseline plasma glu-
cose concentrations. During the ﬁrst hour following insulin
injection,theabsoluteplasmaglucoseconcentrationwassignif-
icantly lower after administration of glulisine than with aspart
(p = 0.0455). Furthermore, the peak glucose concentration
was also signiﬁcantly lower after glulisine administration than
after aspart (p = 0.0337). When considering the overall dura-
tionofthestudy,however,theplasmaglucoselevelsandglucose
excursions were similar between the two rapid-acting insulin
analogues.
Care must be taken when interpreting the PK data, owing
to the different assays used for each insulin analogue. As
analogue-speciﬁc assays were used for determination of aspart
and glulisine, the PK data were normalized to a percentage of
Cmax sothatthedataforthetwoanaloguescouldbecompared.
Although there was no difference between groups over the
study duration, there was a statisticallysigniﬁcant difference in
the measured mean insulin concentration over the ﬁrst 20 min
(ﬁgure 2b). The C-peptide and NEFA levels throughout the
6-h period were comparable in both groups, indicating that
the results were not inﬂuenced by changes in endogenous
insulin secretion and that both insulins have similar effects on
carbohydrate utilization.
Overall, these ﬁndings are consistent with previous results
obtained in a similar study comparing glulisine and lispro in
obese subjects with T2DM [9], which also showed a lower
maximum PPG excursion with glulisine. The ﬁndings are also
consistent with the PD data observed in a study in healthy
individuals [13]. These PK and PD differences could be related
to the zinc-free formulation of glulisine, which, along with the
structuralmodiﬁcations,help to prevent dimerization. Indeed,
these changes facilitate the rapid uptake of glulisine from the
subcutaneous depot after injection [5,6]. The addition of zinc
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Table 2. Pharmacodynamic and pharmacokinetic results.
Estimated sample mean (n = 30)
Glulisine Aspart p value
Estimate and 90% CI
for mean ratios∗
(glulisine/aspart)
Estimate and 90% CI
for mean differences§
(glulisine/aspart)
Pharmacodynamics results
AUC0–1h (mg·h/dl) 149 158 0.0455 94% (90–99) —
AUC0–6h (mg·h/dl) 738 750 0.5382 98% (95–104) —
AUC0–1h/AUC0–6h (%) 20 21 0.0334 95% (92–99) —
AUC0–2h/AUC0–6h (%) 41 42 0.0341 96% (94–99) —
AUC0–4h/AUC0–6h (%) 74 75 0.0912 99% (97–100) —
 GLUmax (mg/dl) 33 40 0.0634 81% (70–100) −8( −15 to −10)
GLUmax (mg/dl) 170 181 0.0337 94% (90–99) −11 (−19 to −3)
Time to  GLUmax (min) 60.0† 59.5† 0.3328 — −5( −20 to 5)¶
Time to 10% of total glucose AUC (min) 40.0† 40.0† 0.3566 — −2( −6t o2 ) ¶
Time to 20% of total glucose AUC (min) 67.5† 65.0† 0.9681 — 0 (−4t o3 ) ¶
Pharmacokinetics results
AUC0–1h (pmol·h/l) 272 (297)‡ 138 (167)‡ <0.0001 197% (157–248) —
AUC0–6h (pmol·h/l) 2002 (2077)‡ 1289 (1333)‡ <0.0001 155% (141–171) —
AUC0–1h/AUC0–6h (%) 14 (2.6)‡ 11 (2.4)‡ 0.0340 127% (106–152) —
AUC0–2h/AUC0–6h (%) 36 (3.6)‡ 35 (3.6)‡ 0.5566 103% (95–110) —
AUC0–4h/AUC0–6h (%) 78 (4.3)‡ 77 (4.3)‡ 0.3716 101% (99–103) —
Cmax (pmol/l) 534 (570)‡ 363 (385)‡ <0.0001 147% (133–163) —
Time to fraction of total insulin AUC (10%) (min) 60.0† 60.5† 0.0372 — −12 (−26 to −1)¶
Time to fraction of total insulin AUC (20%) (min) 90.0† 91.0† 0.9109 — 0 (−12 to 14)¶
Tmax (min) 120.0† 93.0† 0.5133 — 17 (−10 to 37)¶
CI, conﬁdence interval; AUC0–Xh, area under the curve for the period 0–X h;  GLUmax, maximum glucose excursion; GLUmax,p e a kg l u c o s e
concentration; Cmax, peak insulin concentration; Tmax, time to peak insulin concentration.
∗For pharmacodynamic parameters, point estimate and 90% CI for the ratio of treatment means according to Fieller’s Theorem, based on untransformed
data. For pharmacokinetic parameters, point estimate and 90% CI for the ratios of the treatment means, based on ln-transformed data.
†Data are median.
‡Data are sample geometric mean (arithmetic mean).
§Point estimate and 90% CI for the difference of treatment means, from parametric data analysis (analysis of variance), based on untransformed data.
¶Point estimate and 90% CI for the difference of treatment medians from non-parametric analysis (Hodges and Lehmann method).
to the rapid-acting analogues lispro and aspart formulations
is necessary to prevent the formation of ﬁbrils [5,16] and to
promote the formation of stable hexameric and higher-order
aggregates [17,18].
Excess adiposity can adversely affect the PK and PD
properties of RHI [19–21]. Indeed, the site of injection may
inﬂuence the PK and PD of short-acting insulins because
body regions with greater skin thickness may show protracted
absorption [22]. For example, ter Braak et al. reported that the
Cmax and Tmax values for insulin (lispro and human insulin)
varied between the two types of insulin and between the three
injection sites (abdominal, deltoid and femoral sites) [22].
However, in that study, lispro was consistently associated with
better PK and PD parameters vs. RHI, irrespective of the site
of injection. Based on the results of the present study in obese
individuals with T2DM and other studies in lean to obese
subjects without diabetes, it transpires that the onset of action
of the rapid-acting insulin analogues is not delayed in obese
subjects when using a speciﬁc injection site [8]. Unfortunately,
in both studies, the actual subcutaneous fat thickness was
not assessed and BMI per se may not be a good marker for
subcutaneous fat at the injection site.
Overall,theﬁndingsofthepresentstudymustbeconsidered
inlightoftheexploratorynatureofthisstudyandsmallsample
size. It must also be noted that a strictly deﬁned meal size
and content and a ﬁxed insulin dose were used in this study.
Therefore, the results should not be generalized to the popu-
lation as a whole because meal size and content and insulin
doses willvarynotonlybetween individuals but alsoaccording
to meals. However, dose proportionality of glulisine has been
described in individuals with T1DM [11] and it is possible that
a similar effect may be seen in individuals with T2DM; thus,
prospectively altering the insulin dose based on meal content
maybemoreappropriatethanapredeﬁnedtitrationalgorithm
for some individuals [23]. In terms of PD, a similar pattern
is likely to be seen to that observed in this study, but will
clearly depend on the relative carbohydrate and fat content,
aside from the effects of insulin resistance in individuals with
T2DM.
In conclusion, this study, involving obese subjects with
T2DM,showed that,at identicaldoses, glulisine was associated
with a lower plasma glucose level than aspart during the
ﬁrst postprandial hour, in combination with signiﬁcantly
higher glulisine concentrations and when administered by
bolus subcutaneous injection. During the remaining period
of the test, there were no differences in the glucose proﬁles
and glulisine levels were higher than aspart. Taken together,
the lower early and late AUCs for glulisine support the earlier
impact of glulisine, compared with aspart, on the PPG proﬁle
in response to a standard test meal.
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(a)
(b)
Figure 2. (a) Mean plasma insulin concentrations over time and (b) mean plasma insulin concentrations in percentage of peak insulin concentration
over time. ∗p < 0.001 compared with insulin aspart at 10 min and †p > 0.001 compared with insulin aspart at 20 min. SEM, standard of the mean; Cmax,
peak insulin concentration.
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